Sana Biotechnology, Inc. (SANA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Sana Biotechnology skyrockets 200% on positive diabetes study data
Sana Biotechnology Inc skyrocketed over 200% on Wednesday after unveiling positive results from its first in-human diabetes trial. No safety issues were observed four weeks after transplanting Sana's UP421 allogeneic primary islet cell therapy into a type 1 diabetes patient, a statement said.
Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success
Sana Biotechnology, Inc. stock will be surging today after the company showed it can safely administer its allogeneic cell therapy for diabetes to a patient with no immunosuppression. Engineered cells were accepted by the patient's immune system without immunosuppression, a potential game-changing breakthrough that has stumped scientists for >75 years. Although the data is from a single patient, the potential market opportunity for a functional cure for Type 1 diabetes is immense.
Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why
On Tuesday, Sana Biotechnology Inc SANA released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, into a type 1 diabetes patient without the use of any immunosuppression.
Citi keeps $15 target on Sana, says data 'potentially transformative'
Citi says that while the wait for Sana Biotechnology's initial type 1 diabetes data was long, the "reward was well worth it as Sana has delivered what looks to be potentially transformative data," the analyst tells investors in a research note. The data demonstrate a "major scientific advance" for type 1 diabetes patients as it suggests Sana's hypoimmune edits permit islet cell transplant survival in the absence of immunosuppression, the analyst tells investors in a research note. Citi believes the implications extend beyond type 1 diabetes and islet cells though, and could potentially be applied broadly within the allogeneic field. The firm anticipates the stock could continue to appreciate after the open today and keeps a Buy rating on the name with a $15 price target. Sana in premarket trading is up 274%, or $4.52, to $6.17.
H.C. Wainwright ups Sana target after 'best case scenario' data
H.C. Wainwright raised the firm's price target on Sana Biotechnology to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for SC451 to 15% from 10% based on today's data and for SC291 for autoimmune diseases to 20% from 15% based on the Phase 1 data and progress from competitor allogeneic CAR-T programs in the space. The first patient dosed with hypoimmune islet cells showcased cell survive and function without immunosuppression, the analyst tells investors in a research note. H.C. Wainwright says the patient met all the primary and secondary trial endpoints. It views the data as the "best case scenario" for the initial type 1 diabetes update.
This Biotech Stock Just Soared 240%. Why It Can Go Higher.
The shares are at about $5 now, and strategists see a chance they could go to $10.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
